Multiple Sclerosis and Related Disorders

MS susceptibility in Latin American populations 2:06
MS susceptibility in Latin American populations
Victor Rivera • 24 Feb 2022
Developing a natural model for MS 1:53
Developing a natural model for MS
Jorge Alvarez • 25 Feb 2022
Using machine learning predictions to design more efficient MS clinical trials 5:28
Using machine learning predictions to design more efficient MS clinical trials
David Li-Bland • 2 Mar 2022
Impact of ocrelizumab disruption on RRMS 2:52
Impact of ocrelizumab disruption on RRMS
Kelly Cotchett • 25 Feb 2022
Research developments in MOGAD 1:23
Research developments in MOGAD
Michael Levy • 25 Feb 2022
The earliest stages of MS: understanding susceptibility and the MS prodrome 1:32
The earliest stages of MS: understanding susceptibility and the MS prodrome
Adil Harroud • 25 Feb 2022
SAkura: long-term safety and efficacy of satralizumab for NMOSD 1:27
SAkura: long-term safety and efficacy of satralizumab for NMOSD
Michael Levy • 25 Feb 2022
Biology or poor trial design…What underlies remyelination trial failures in MS? 4:50
Biology or poor trial design…What underlies remyelination trial failures in MS?
Gavin Giovannoni • 1 Mar 2022
Tailoring treatment in MS with new S1P receptor modulators 1:01
Tailoring treatment in MS with new S1P receptor modulators
Jiwon Oh • 25 Feb 2022
BTK inhibitors: Investigating disease relevant mechanisms in multiple sclerosis 3:51
BTK inhibitors: Investigating disease relevant mechanisms in multiple sclerosis
Rochelle Benoit • 28 Feb 2022
Paramagnetic rim lesions in multiple sclerosis 1:13
Paramagnetic rim lesions in multiple sclerosis
Jiwon Oh • 25 Feb 2022
What is the latest progress in gene research in MS? 2:07
What is the latest progress in gene research in MS?
Lars Alfredsson • 25 Feb 2022
Investigating the MS prodrome and RIS to advance understanding in MS 2:18
Investigating the MS prodrome and RIS to advance understanding in MS
Adil Harroud • 25 Feb 2022
Recent progress and future needs in NMOSD treatment 1:39
Recent progress and future needs in NMOSD treatment
Michael Levy • 25 Feb 2022
Potential of BTK inhibitors in MS 1:46
Potential of BTK inhibitors in MS
Rochelle Benoit • 28 Feb 2022
Investigating the impact of at-home training and tDCS on cognitive function in MS 1:44
Investigating the impact of at-home training and tDCS on cognitive function in MS
Leigh Charvet • 26 Feb 2022
The content of VJNeurology is intended for healthcare professionals